Ticker > Company >

Zim Laboratories share price

Zim Laboratories Ltd.

NSE: ZIMLAB BSE: 541400 SECTOR: Pharmaceuticals & Drugs  25k   26   4

99.88
-0.91 (-0.90%)
BSE: 06 Jun 04:01 PM

Price Summary

Today's High

₹ 101.77

Today's Low

₹ 99.44

52 Week High

₹ 128.45

52 Week Low

₹ 79.5

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

486.67 Cr.

Enterprise Value

597.9 Cr.

No. of Shares

4.87 Cr.

P/E

41.44

P/B

2

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  49.9

CASH

0.82 Cr.

DEBT

112.05 Cr.

Promoter Holding

33.26 %

EPS (TTM)

₹  2.41

Sales Growth

2.78%

ROE

4.94 %

ROCE

8.35%

Profit Growth

-29.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.78%
3 Year4.47%
5 Year6.49%

Profit Growth

1 Year-29.91%
3 Year-3.36%
5 Year46.5%

ROE%

1 Year4.94%
3 Year8.85%
5 Year7.63%

ROCE %

1 Year8.35%
3 Year11.98%
5 Year11.22%

Debt/Equity

0.4608

Price to Cash Flow

9.62

Interest Cover Ratio

2.5468

CFO/PAT (5 Yr. Avg.)

2.44296639879785

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 33.26 0.00
Dec 2024 33.26 0.00
Sep 2024 33.26 0.00
Jun 2024 33.26 0.00
Mar 2024 33.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 29.3617 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.44296639879785.

 Limitations

  • The company has shown a poor profit growth of -3.36188965281501% for the Past 3 years.
  • The company has shown a poor revenue growth of 4.46552269367557% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 117.39 82 89.72 95.4 108.52
Total Expenditure 101.96 74.13 81.33 83.63 93.28
Operating Profit 15.42 7.88 8.39 11.77 15.24
Other Income 1.53 0.98 1.32 1.77 1.55
Interest 2.28 2.86 2.89 2.73 2.91
Depreciation 3.88 4.92 4.97 4.77 5.23
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.8 1.08 1.85 6.03 8.65
Tax 2.91 0.33 0.64 1.68 3.23
Profit After Tax 7.89 0.76 1.22 4.35 5.42
Adjusted EPS (Rs) 1.62 0.16 0.25 0.89 1.11

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 303.63 329.49 396.53 365.47 375.64
Total Expenditure 266.82 291.56 345.34 325.37 332.37
Operating Profit 36.81 37.93 51.19 40.1 43.27
Other Income 2.45 4.51 6.43 4.69 5.62
Interest 10.89 8.31 5.58 6.92 11.39
Depreciation 14.61 14.84 16.13 14.83 19.89
Exceptional Items -5.18 0 0 0 0
Profit Before Tax 8.58 19.3 35.92 23.04 17.61
Tax 2.96 6.28 10.91 6.28 5.87
Net Profit 5.62 13.01 25.01 16.76 11.74
Adjusted EPS (Rs.) 1.15 2.67 5.13 3.44 2.41

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 16.24 16.24 48.73 48.73 48.73
Total Reserves 140.81 153.86 145.45 183.23 195.79
Borrowings 21.83 18.92 24.62 35.6 40.3
Other N/C liabilities -2.36 1.09 12.1 13.05 13.37
Current liabilities 141.23 146.76 110.24 161.9 166.2
Total Liabilities 317.75 336.88 341.15 442.5 464.39
Assets
Net Block 103.15 103.31 107.15 160.49 163.6
Capital WIP 4.56 5.1 17.84 23.52 44.05
Intangible WIP 5.9 6.33 8.42 16.73 21.61
Investments 8.08 8.18 8.18 8.23 13.04
Loans & Advances 11.25 11.64 20.4 15.51 4.97
Other N/C Assets 1.85 0.28 0.52 0.31 0.76
Current Assets 182.97 202.05 178.64 217.71 216.35
Total Assets 317.75 336.88 341.15 442.5 464.39
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 13.76 19.3 35.92 23.04 17.61
Adjustment 24.61 20.76 20.81 21.36 31.47
Changes in Assets & Liabilities -5.41 7.2 -14.52 -30.36 0.24
Tax Paid -1.06 -0.23 -6.98 -2.57 1.29
Operating Cash Flow 31.9 47.03 35.23 11.47 50.6
Investing Cash Flow -5.7 -14.42 -35.21 -71.94 -41.31
Financing Cash Flow -25.96 -32.97 0.55 59.53 -9.1
Net Cash Flow 0.23 -0.36 0.57 -0.94 0.19

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 33.26 33.26 33.26 33.26 33.26
anwar daud - 27.37 27.37 27.37 27.37
hasan kamal 0.21 0.21 0.21 0.21 0.21
sabbah zulfiquar kamal 3.08 3.08 3.08 3.08 3.08
shabbar daud - 0.09 0.09 0.09 0.09
tasneem anwar daud 0.06 0.06 0.06 0.06 0.06
zulfiquar murtuza kamal - 2.45 2.45 2.45 2.45
anwar siraj daud 27.37 - - - -
shabbar siraj daud 0.09 - - - -
zulfiquar kamal 2.45 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 66.74 66.74 66.74 66.74 66.74
bonanza business services... 2.54 2.54 2.54 2.54 2.54
dhoot industrial finance ... - - - 1.35 1.44
dr iguer abdelmounaim 2.39 2.39 2.39 2.39 2.39
elizabeth mathew - - - - 12.02
investor education and pr... - 3.03 3.03 3.59 3.59
jyoti bharat sheth - - 1.38 1.38 1.38
laadki trading and invest... - - 1.37 1.37 1.37
llp 0.24 0.09 0.26 0.21 0.13
zakir s vali 10.36 10.36 10.36 10.36 10.36
elimath advisors private ... - - 3.37 3.17 -
mathew cyriac 14.58 14.16 9.83 9.83 -
investor education and pr... 3.03 - - - -
yuga stocks and commoditi... 1.22 - - - -

Ratings & Research Reports

Company Presentations

Company News

Zim Laboratories - Quaterly Results 20 May, 8:30 PM Zim Laboratories - Quaterly Results 20 May, 8:30 PM Zim Laboratories informs about outcome of board meeting 28 Apr, 4:18 PM ZIM Laboratories inks pact with Globalpharma to commercialize oral thin film products 9 Apr, 6:14 PM ZIM Laboratories’ arm gets marketing authorization for Dimethyl Fumarate Capsules 20 Mar, 11:30 AM Zim Laboratories - Quaterly Results 10 Feb, 7:40 PM Zim Laboratories - Quaterly Results 10 Feb, 7:40 PM Zim Laboratories informs about closure of trading window 27 Dec, 5:11 PM ZIM Laboratories’ arm incorporates subsidiary in Dubai 16 Nov, 11:15 AM Zim Laboratories - Quaterly Results 9 Nov, 7:36 PM Zim Laboratories - Quaterly Results 9 Nov, 7:36 PM ZIM Laboratories gets nod to invest in equity shares of SIA ZIM Laboratories 1 Oct, 2:24 PM ZIM Laboratories informs about analyst meet 26 Aug, 5:11 PM Zim Laboratories informs about newspaper publication 5 Aug, 4:38 PM ZIM Laboratories gets nod to invest in SIA ZIM Laboratories 5 Aug, 10:13 AM Zim Laboratories - Quaterly Results 3 Aug, 6:28 PM Zim Laboratories - Quaterly Results 3 Aug, 6:28 PM ZIM Laboratories’ arm gets nod to market ‘Azithromycin for Oral Suspension’ in Portugal 23 Jul, 10:22 AM ZIM Laboratories invests Rs 68.25 lakh in ZIMTAS 2 Jul, 3:42 PM ZIM Laboratories informs about analyst meet 14 Jun, 2:31 PM ZIM Laboratories gets nod to invest Rs 40 lakh in SIA ZIM Laboratories 14 May, 9:59 AM ZIM Laboratories gets nod to invest Rs 2 crore in ZIMTAS 14 May, 9:39 AM Zim Laboratories - Quaterly Results 13 May, 9:29 PM Zim Laboratories - Quaterly Results 13 May, 9:29 PM Zim Laboratories informs about credit rating 6 Apr, 3:15 PM Zim Laboratories - Quaterly Results 29 Jan, 4:15 PM Zim Laboratories - Quaterly Results 29 Jan, 4:15 PM Zim Laboratories - Quaterly Results 29 Jan, 4:15 PM Zim Laboratories informs about details of loss of certificate 1 Jan, 5:02 PM Zim Laboratories informs about closure of trading window 29 Dec, 5:01 PM Zim Laboratories informs about loss of share certificate 22 Dec, 4:53 PM Zim Laboratories informs about loss of share certificates 5 Dec, 4:34 PM Zim Laboratories submits analyst meet intimation 4 Dec, 1:08 PM ZIM Laboratories informs about investor meet 25 Nov, 3:39 PM Zim Laboratories informs about analyst meet 21 Nov, 3:21 PM Zim Laboratories informs about transcript of earnings conference call 15 Nov, 12:38 PM Zim Laboratories - Quaterly Results 1 Nov, 8:02 PM Zim Laboratories - Quaterly Results 1 Nov, 8:02 PM Zim Laboratories informs about board meeting 21 Oct, 3:32 PM ZIM Laboratories incorporates step-down Subsidiary 14 Oct, 2:36 PM Zim Laboratories informs about analyst meet 15 Sep, 5:06 PM Zim Laboratories informs about analyst meet 14 Sep, 2:26 PM Zim Laboratories informs about analyst meet 14 Sep, 2:03 PM Zim Laboratories informs about loss of share certificates 6 Sep, 5:14 PM Zim Laboratories informs about transcript of earnings call 21 Aug, 10:32 AM Zim Laboratories - Quaterly Results 14 Aug, 6:39 PM Zim Laboratories - Quaterly Results 14 Aug, 6:39 PM ZIM Laboratories informs about disclosure 8 Aug, 2:29 PM Zim Laboratories informs about loss of share certificate 29 Jul, 3:10 PM Zim Laboratories informs about AGM 10 Jul, 5:18 PM

Zim Laboratories Stock Price Analysis and Quick Research Report. Is Zim Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Zim Laboratories and its performance over the period of time. Zim Laboratories stock price today is Rs 99.96.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Zim Laboratories cash from the operating activity was Rs 50.602 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Zim Laboratories has a Debt to Equity ratio of 0.4608 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Zim Laboratories , the EPS growth was -29.9096 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Zim Laboratories has OPM of 11.5187196098345 % which is a bad sign for profitability.
     
  • ROE: Zim Laboratories have a poor ROE of 4.9437 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Zim Laboratories is Rs 99.96. One can use valuation calculators of ticker to know if Zim Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Zim Laboratories
X